Abstract
Challenges with surgical treatment of glaucoma are numerous and frequent, especially with the more complicated forms such as neovascular or uveitic glaucoma. Surgeries often fail which have driven the search for using a surgical adjunct to improve the outcomes and longevity of glaucoma procedures, while lowering their complication rates. VEGF levels have been found to be elevated in patients with both primary open angle glaucoma and secondary glaucomas. The use of anti-VEGF agents is now being investigated in the treatment of all types of glaucoma. The information is early and limited, but what is known will be reviewed in this article. In considering anti-VEGF agents in the treatment of glaucoma, some evidence suggests that anti-VEGF agents may induce glaucoma by elevating intraocular pressure, which will also be reviewed.
Keywords: Antivascular endothelial growth factor, bevacizumab, bleb, glaucoma, intraocular pressure, mitomycin C, neovascular glaucoma, ranibizumab, trabeculectomy, glaucoma, surgery
Current Drug Therapy
Title:Anti-VEGF Treatment of Glaucoma
Volume: 7 Issue: 2
Author(s): Rick E. Bendel
Affiliation:
Keywords: Antivascular endothelial growth factor, bevacizumab, bleb, glaucoma, intraocular pressure, mitomycin C, neovascular glaucoma, ranibizumab, trabeculectomy, glaucoma, surgery
Abstract: Challenges with surgical treatment of glaucoma are numerous and frequent, especially with the more complicated forms such as neovascular or uveitic glaucoma. Surgeries often fail which have driven the search for using a surgical adjunct to improve the outcomes and longevity of glaucoma procedures, while lowering their complication rates. VEGF levels have been found to be elevated in patients with both primary open angle glaucoma and secondary glaucomas. The use of anti-VEGF agents is now being investigated in the treatment of all types of glaucoma. The information is early and limited, but what is known will be reviewed in this article. In considering anti-VEGF agents in the treatment of glaucoma, some evidence suggests that anti-VEGF agents may induce glaucoma by elevating intraocular pressure, which will also be reviewed.
Export Options
About this article
Cite this article as:
E. Bendel Rick, Anti-VEGF Treatment of Glaucoma, Current Drug Therapy 2012; 7 (2) . https://dx.doi.org/10.2174/157488512800675995
DOI https://dx.doi.org/10.2174/157488512800675995 |
Print ISSN 1574-8855 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3903 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Soluble CD40L and its Role in Essential Hypertension: Diagnostic and Therapeutic Implications
Cardiovascular & Hematological Disorders-Drug Targets Targeting IL-17 and IL-23 in Immune Mediated Renal Disease
Current Medicinal Chemistry Nitric Oxide in Cardiac Transplantation
Vascular Disease Prevention (Discontinued) Calcific Aortic Stenosis: Molecular and Cellular Mechanisms, Medical Treatment Alternatives
Current Cardiology Reviews Mental and Emotional Wellbeing During the COVID-19 Pandemic: The Unprecedented Malaysian Experience
Current Psychiatry Research and Reviews Pharmacogenetics in Methadone Therapy
Current Pharmacogenomics and Personalized Medicine Changes in the Density of Corneal Endothelial Cells in Elderly Diabetic Patients After Combined Phacovitrectomy and Ex-PRESS Glaucoma Implants
Current Pharmaceutical Biotechnology Non-pharmacological Strategies Against Systemic Inflammation: Molecular Basis and Clinical Evidence
Current Pharmaceutical Design The Role of Statins in Preventing the Progression of Congestive Heart Failure in Patients with Metabolic Syndrome
Current Pharmaceutical Design Altered Prolylcarboxypeptidase Expression and Function in Response to Different Risk Factors of Diabetes
Cardiovascular & Hematological Agents in Medicinal Chemistry Management and Treatment of Cardiovascular Diseases in the Elderly
Current Pharmacogenomics and Personalized Medicine Collateral Circulation in Chronic Total Occlusions – an interventional perspective
Current Cardiology Reviews Traditional Risk Factors for Coronary Atherosclerosis in Indo Asians: The Need for a Reappraisal
Current Pharmaceutical Design New Insight Into A1 Adenosine Receptors in Diabetes Treatment
Current Pharmaceutical Design Editorial [Hot Topic:Genetic Disorders of Hemoglobin: Sickle Cell Anemia and Thalassemia (Guest Editors: Elliott Vichinsky, Griffin P. Rodgers and Eliezer Rachmilewitz)]
Current Molecular Medicine Synthetic Approaches to the 2006 New Drugs
Mini-Reviews in Medicinal Chemistry The Role of Matrix Metalloproteinases in Essential Hypertension
Current Topics in Medicinal Chemistry Bariatric Surgery: Indications, Safety and Efficacy
Current Pharmaceutical Design The Tumor Necrosis Factor-Derived TIP Peptide: A Potential Anti-Edema Drug
Letters in Drug Design & Discovery The Glucocorticoid Receptor: Molecular Mechanism and New Therapeutic Opportunities
Current Drug Targets - Inflammation & Allergy